Comparing new treatments for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back or did not respond after 1 to 3 prior treatments.
- Your past treatments included lenalidomide and either a proteasome inhibitor (like bortezomib) or a type of antibody (anti-CD38).
- Your disease has gotten worse during or after your last treatment.
- You are well enough to do daily activities (ECOG score of 0, 1, or 2).
- You have not had a prior therapy that targets BCMA using T cells (like CAR-T or bispecific antibodies).
- You do not have plasma cell leukemia, amyloidosis, Waldenström macroglobulinemia, POEMS syndrome, or myeloma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
This trial compares a new drug called linvoseltamab to standard treatments for multiple myeloma. It is for people who cannot have a stem cell transplant and have not had extensive prior therapy.
Hear when a new Relapsed and/or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.